The Frist School of Clinical Medicine, 12426Lanzhou University, Lanzhou, China.
Department of Surgical Oncology, 91589Gansu Provincial Hospital, Lanzhou, China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154094. doi: 10.1177/15330338231154094.
In this meta-analysis, we investigated the safety and efficacy of carbon nanoparticle (CNP) trace-guided lymph node (LN) dissection during radical gastrectomy. Literature on CNP tracing compared with non-CNP tracing in radical gastric cancer (GC) surgery was searched from PubMed, EMBASE (Ovid platform), Web of Science, and the Cochrane Library from the establishment of the library until October 2022. This meta-analysis was performed according to the preferred reporting items for systematic reviews and meta-analysis guidelines. Available data regarding the number of LNs dissected, number of metastatic LNs dissected, other surgical outcomes, and postoperative complications were analyzed in a pooled manner. Stata software (version 12.0) was used for the present meta-analysis. This analysis included 7 studies with a total of 1827 GC patients (551 and 1276 in the CNP and non-CNP groups, respectively). The results of the meta-analysis showed that the CNP group had more intraoperative LNs detected [weighted mean difference (WMD) = 6.67, 95% confidence interval (CI): 3.71-9.62], more LN metastases (WMD = 1.60, 95% CI: 0.09-3.12), and less intraoperative bleeding (WMD = 11.33, 95% CI: 6.30-16.37) than the non-CNP group, all with statistically significant differences ( < .05). For postoperative complications (odds ratio [OR] = 0.88, 95% CI: 0.52-1.48) and operative time (WMD = -11.60, 95% CI: -40.53-17.34), there was no statistically significant difference between the 2 groups ( > 0.05). CNP was a significant tracer for the LNs of GC. It increased the number of LNs harvested while reducing intraoperative blood loss, without increasing the operative time or postoperative complications. CNP tracer-guided lymphadenectomy is considered safe and effective for gastrectomy.
在这项荟萃分析中,我们研究了碳纳米粒子(CNP)示踪引导在根治性胃切除术中的安全性和有效性。从 PubMed、EMBASE(Ovid 平台)、Web of Science 和 Cochrane Library 中检索了 CNP 示踪与根治性胃癌(GC)手术中非 CNP 示踪的文献,检索时间截至 2022 年 10 月。本荟萃分析按照系统评价和荟萃分析报告的首选条目进行。以汇总的方式分析了可获得的关于切除的淋巴结数量、转移淋巴结数量、其他手术结果和术后并发症的数据。使用 Stata 软件(版本 12.0)进行本次荟萃分析。该分析包括 7 项研究,共纳入 1827 例 GC 患者(CNP 组 551 例,非 CNP 组 1276 例)。荟萃分析结果显示,CNP 组术中检测到的淋巴结更多[加权均数差(WMD)=6.67,95%置信区间(CI):3.71-9.62],淋巴结转移更多(WMD=1.60,95%CI:0.09-3.12),术中出血量更少(WMD=11.33,95%CI:6.30-16.37),差异均有统计学意义(<0.05)。对于术后并发症(比值比[OR] = 0.88,95%CI:0.52-1.48)和手术时间(WMD =-11.60,95%CI:-40.53-17.34),两组间无统计学差异(>0.05)。CNP 是 GC 淋巴结的一种显著示踪剂。它增加了淋巴结的检出数量,同时减少了术中出血量,而不增加手术时间或术后并发症。CNP 示踪剂引导的淋巴结清扫术被认为是安全有效的胃切除术。